This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Dapagliflozin
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict WATCH-LIST MEDIUM
Among the most exciting metabolic drug classes of the last 15 years — replicated mortality reduction in HF + CKD across multiple Phase 3 trials, independent of diabetes status. Real longevity interest. For a 20yo healthy male: no current indication, mechanism (renal glucose dumping) imposes mild dehydration + caloric loss + theoretical DKA risk with low-carb eating. WATCH-LIST as a longevity tool to monitor — flips to OPTIONAL-ADD if Dylan develops metabolic risk markers (insulin resistance, hypertension, early CKD) at any future age, OR if convincing data emerges for healthy-aging populations (NIA-funded SGLT2-in-aging studies underway).
▸ Verdict change log
- 2026-06-05 — Initial verdict WATCH-LIST. (stub)
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.